NeOnc phase 2a trial of intranasal NEO100 meets primary endpoint

August 12, 2026 8:00 AM

NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) reported positive topline results from the Phase 2a portion of its NEO100-01 study, an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found